You quote: "sparsentan and irbesartan had similar safety profiles, and the frequency of adverse events was similar in the two groups”
Yes - and they were similarly bad:
"In terms of safety, the rate of serious, treatment-related adverse events was similar between the two groups (37% in the sparsentan group and 43.9% in the irbesartan group). Although there were more episodes of hyperkalemia (16.8% vs. 10.7%) and hypotension (17.9% vs. 11.2%) in the sparsentan group, there was no increased risk of peripheral edema (19.6% vs. 21.9%)"
https://www.theisn.org/blog/2024/02...trial-new-selection-of-global-trials-out-now/
You quote: "sparsentan and irbesartan had similar safety...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 337999 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 17466 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |